What to Do and What Not to Do in the Management of Opioid-Induced Constipation: A Choosing Wisely Report
Tóm tắt
Despite the essential utility of opioids for the clinical management of pain, opioid-induced constipation (OIC) remains an important obstacle in clinical practice. In patients, OIC hinders treatment compliance and has negative effects on quality of life. From a clinician perspective, the diagnosis and management of OIC are hampered by the absence of a clear, universal diagnostic definition across disciplines and a lack of standardization in OIC treatment and assessment. A multidisciplinary panel of physician experts who treat OIC was assembled to identify a list of ten corrective actions—five “things to do” and five “things not to do”—for the diagnosis and management of OIC, utilizing the Choosing Wisely methodology. The final list of corrective actions to improve the diagnosis and clinical management of OIC emphasized a need for: (i) better physician and patient education regarding OIC; (ii) systematic use of diagnostically validated approaches to OIC diagnosis and assessment (i.e., Rome IV criteria and Bristol Stool Scale, respectively) across various medical contexts; and (iii) awareness about appropriate, evidence-based treatments for OIC including available peripheral mu-opioid receptor antagonists (PAMORAs). Physicians who prescribe long-term opioids should be forthcoming with patients about the possibility of OIC and be adequately versed in the most recent guideline recommendations for its management.
Tài liệu tham khảo
Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009;5(3):137–44.
Sizar O, Gupta M. Opioid Induced constipation. Treasure Island: StatPearls, StatPearls Publishing; 2019.
Andresen V, Banerji V, Hall G, et al. The patient burden of opioid-induced constipation: new insights from a large, multinational survey in five European countries. United Eur Gastroenterol J. 2018;6(8):1254–66.
Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23(3):229–35.
Drewes AM, Munkholm P, Simren M, et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scand J Pain. 2016;11:11–22.
Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22(4):424–30 (e96).
Troberg K, Hakansson A, Dahlman D. Self-rated physical health and unmet healthcare needs among swedish patients in opioid substitution treatment. J Addict. 2019;2019:7942145. https://doi.org/10.1155/2019/7942145.
Lugoboni F, Mirijello A, Zamboni L, et al. High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. Expert Opin Pharmacother. 2016;17(16):2135–41.
Ducrotte P, Milce J, Soufflet C, et al. Prevalence and clinical features of opioid-induced constipation in the general population: a French study of 15,000 individuals. United European Gastroenterol J. 2017;5(4):588–600.
Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224–32.
National Institute for Health and Care Excellence. Costing statement: Naloxegol for treating opioid-induced constipation (TA345). 2015.
Brenner DM, Stern E, Cash BD. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep. 2017;19(3):12.
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015;9(5):358–67.
Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United Eur Gastroenterol J. 2019;7(1):7–20.
Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag. 2009;5(3):145–51.
Klein J, Holowaty S. Managing constipation: implementing a protocol in a geriatric rehabilitation setting. J Gerontol Nurs. 2014;40(8):18–27.
Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2015;49(1):9–16.
Cosci F. “Bowel obsession syndrome” in a patient with chronic constipation. Gen Hosp Psychiatry. 2013;35(4):451e1-3.
Simren M, Palsson OS, Whitehead WE. Update on rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15.
Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151–63.
Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(9):1582–91.
Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Thera Adv Gastroenterol. 2015;8(4):206–20.
Joshi GP, Kehlet H. Postoperative pain management in the era of ERAS: an overview. Best Pract Res Clin Anaesthesiol. 2019;33(3):259–67.
Jain N, Brock JL, Phillips FM, et al. Chronic preoperative opioid use is a risk factor for increased complications, resource use, and costs after cervical fusion. Spine J. 2018;18(11):1989–98.
Jain N, Phillips FM, Weaver T, et al. Preoperative chronic opioid therapy: a risk factor for complications, readmission, continued opioid use and increased costs after one- and two-level posterior lumbar fusion. Spine (Phila Pa 1976). 2018;43(19):1331–8.
Coluzzi F, Bifulco F, Cuomo A, et al. The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag. 2017;13:1163–73.
Pergolizzi JV, Lequang JA, Passik S, et al. Using opioid therapy for pain in clinically challenging situations: questions for clinicians. Minerva Anestesiol. 2019;85(8):899–908.
Streicher JM, Bilsky EJ. Peripherally acting mu-opioid receptor antagonists for the treatment of opioid-related side effects: mechanism of action and clinical implications. J Pharm Pract. 2018;31(6):658–69.
Emmanuel A, Johnson M, McSkimming P, et al. Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. Pain Med. 2017;18(10):1932–40.
Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig. 2015;35(1):1–11.
Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(5):360–7.
Pergolizzi JV Jr, Christo PJ, LeQuang JA, et al. The use of peripheral mu-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety. Drug Des Dev Ther. 2020;14:1009–25.
Murphy JA, Sheridan EA. Evidence based review of pharmacotherapy for opioid-induced constipation in noncancer pain. Ann Pharmacother. 2018;52(4):370–9.
Gazzetta Ufficiale della Republica Italiana Anno 161° - Numero 111 del 30 Aprile 2020.
Salix Pharmaceuticals Inc. Relistor® (methylnaltrexone bromide subcutaneous injection). Raleigh: Full Prescribing Information; 2014.
AstraZeneca AB. Moventig® (naloxegol). Södertälje: Full Prescribing Information; 2015.
Coluzzi F, Scerpa MS, Pergolizzi J. Naldemedine: a new option for OIBD. J Pain Res. 2020;13:1209–22.
Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol. 2017;35(34):3859–66.
Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann Oncol. 2018;29(6):1461–7.
Saito Y, Yokota T, Arai M, et al. Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies. J Pain Res. 2019;12:127–38.
Blair HA. Naldemedine: a review in opioid-induced constipation. Drugs. 2019;79(11):1241–7.
Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain. 2019;35(2):174–88.
Cook SF, Bell T, Sweeny CT, et al. Impact on quality of life of constipation associated GI symptoms related to opioid treatment in chronic pain patients: pAC-QoL results from the opioid survey, In: 26th Annual Scientific Meeting of the American Pain Society, 2007.
Duenas M, Ojeda B, Salazar A, et al. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457–67.
Singh R, Pushkin GW. How Should medical education better prepare physicians for opioid prescribing? AMA J Ethics. 2019;21(8):E636–41.
Frantsve LM, Kerns RD. Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making. Pain Med. 2007;8(1):25–35.